ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $48.21 million. The enterprise value is $56.85 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 9.05 million shares outstanding. The number of shares has increased by 14.38% in one year.
| Current Share Class | 9.05M |
| Shares Outstanding | 9.05M |
| Shares Change (YoY) | +14.38% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 28.07% |
| Owned by Institutions (%) | 18.36% |
| Float | 6.00M |
Valuation Ratios
The trailing PE ratio is 20.18.
| PE Ratio | 20.18 |
| Forward PE | n/a |
| PS Ratio | 1.69 |
| Forward PS | n/a |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.59 |
| P/FCF Ratio | 65.88 |
| P/OCF Ratio | 23.69 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 10.46, with an EV/FCF ratio of 79.47.
| EV / Earnings | 24.46 |
| EV / Sales | 2.05 |
| EV / EBITDA | 10.46 |
| EV / EBIT | 20.78 |
| EV / FCF | 79.47 |
Financial Position
The company has a current ratio of 4.21, with a Debt / Equity ratio of 0.46.
| Current Ratio | 4.21 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 2.29 |
| Debt / FCF | 19.02 |
| Interest Coverage | 5.23 |
Financial Efficiency
Return on equity (ROE) is 8.27% and return on invested capital (ROIC) is 4.01%.
| Return on Equity (ROE) | 8.27% |
| Return on Assets (ROA) | 3.79% |
| Return on Invested Capital (ROIC) | 4.01% |
| Return on Capital Employed (ROCE) | 6.56% |
| Revenue Per Employee | $370,257 |
| Profits Per Employee | $30,982 |
| Employee Count | 75 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.85 |
Taxes
In the past 12 months, ImmuCell has paid $14,300 in taxes.
| Income Tax | 14,300 |
| Effective Tax Rate | 0.61% |
Stock Price Statistics
The stock price has increased by +16.38% in the last 52 weeks. The beta is 0.21, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +16.38% |
| 50-Day Moving Average | 5.88 |
| 200-Day Moving Average | 5.88 |
| Relative Strength Index (RSI) | 46.47 |
| Average Volume (20 Days) | 20,585 |
Short Selling Information
The latest short interest is 5,568, so 0.06% of the outstanding shares have been sold short.
| Short Interest | 5,568 |
| Short Previous Month | 5,921 |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.09% |
| Short Ratio (days to cover) | 0.24 |
Income Statement
In the last 12 months, ImmuCell had revenue of $27.77 million and earned $2.32 million in profits. Earnings per share was $0.26.
| Revenue | 27.77M |
| Gross Profit | 11.77M |
| Operating Income | 2.74M |
| Pretax Income | 2.34M |
| Net Income | 2.32M |
| EBITDA | 5.43M |
| EBIT | 2.74M |
| Earnings Per Share (EPS) | $0.26 |
Full Income StatementBalance Sheet
The company has $3.89 million in cash and $13.61 million in debt, giving a net cash position of -$9.72 million or -$1.07 per share.
| Cash & Cash Equivalents | 3.89M |
| Total Debt | 13.61M |
| Net Cash | -9.72M |
| Net Cash Per Share | -$1.07 |
| Equity (Book Value) | 29.80M |
| Book Value Per Share | 3.29 |
| Working Capital | 12.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.99 million and capital expenditures -$1.27 million, giving a free cash flow of $715,351.
| Operating Cash Flow | 1.99M |
| Capital Expenditures | -1.27M |
| Free Cash Flow | 715,351 |
| FCF Per Share | $0.08 |
Full Cash Flow StatementMargins
Gross margin is 42.40%, with operating and profit margins of 9.85% and 8.37%.
| Gross Margin | 42.40% |
| Operating Margin | 9.85% |
| Pretax Margin | 8.42% |
| Profit Margin | 8.37% |
| EBITDA Margin | 19.56% |
| EBIT Margin | 9.85% |
| FCF Margin | 2.58% |
Dividends & Yields
ImmuCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.38% |
| Shareholder Yield | -14.38% |
| Earnings Yield | 4.93% |
| FCF Yield | 1.52% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmuCell has an Altman Z-Score of 2.54 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.54 |
| Piotroski F-Score | 7 |
